Article Sidebar

PDF (Tiếng Việt)
Published: 2025-12-30
Abstract Views: 0
Views PDF (Tiếng Việt): 0
DOI: https://doi.org/10.52852/tcncyh.v197i12.4165
Issue
Vol. 197 No. 12 (2025)
Section
Các bài báo
How to Cite
Hùng, N. V., Linh, T. L., Thái, L. H., Toàn, P. K., Mạnh, P. D., Bách, T. T., Ngân, M. T. K., Anh, T. Đình, Anh, T. T. K., Huy, T. L., & Trí, N. M. (2025). Factors associated with treatment outcomes of metastatic esophageal cancer using the mDCF regimen at Hanoi Medical University Hospital. Journal of Medical Research, 197(12), 248-258. https://doi.org/10.52852/tcncyh.v197i12.4165

Factors associated with treatment outcomes of metastatic esophageal cancer using the mDCF regimen at Hanoi Medical University Hospital

Nguyen Van Hung, Tran Ly Linh, Le Hong Thai, Phan Khanh Toan, Pham Duy Manh, Tran Trung Bach, Mai Thi Kim Ngan, Tran Dinh Anh, Tran Thi Kim Anh, Trinh Le Huy, Ngo Minh Tri

Main Article Content

Abstract

A retrospective study was conducted to evaluate factors associated with treatment outcomes in patients with metastatic esophageal cancer receiving the mDCF chemotherapy regimen at Hanoi Medical University Hospital. 40 patients with metastatic esophageal cancer who had received at least four cycles of mDCF were included in the analysis. The results showed that the median progression-free survival (PFS) and overall survival (OS) were 6.4 months and 12.1 months, respectively. Multivariate regression analysis identified the number of chemotherapy cycles and treatment response as statistically significant prognostic factors. Other characteristics, including age, tumor location, T stage, number of metastatic sites, and chemotherapy dose, were not significantly associated with prognosis. The mDCF regimen demonstrated favorable efficacy in patients with metastatic esophageal cancer.

Article Details

Keywords

Esophageal cancer, metastasis, mDCF, prognosis, Hanoi Medical University Hospital

References

1. Bray F, Laversanne M, Sung H, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: A Cancer Journal for Clinicians. 2024; 74(3): 229-263. doi:10.3322/caac.21834.
2. Chen MQ, Xu BH, Zhang YY. Analysis of prognostic factors for esophageal squamous cell carcinoma with distant organ metastasis at initial diagnosis. Journal of the Chinese Medical Association. 2014; 77(11): 562-566. doi:10.1016/j.jcma.2014.05.014.
3. Wagner AD, Syn NL, Moehler M, et al. Chemotherapy for advanced gastric cancer. Cochrane Database Syst Rev. 2017; 8: CD004064. doi:10.1002/14651858.CD004064.pub4.
4. Janjigian YY, Maron SB, Chatila WK, et al. First-line pembrolizumab and trastuzumab in HER2-positive oesophageal, gastric, or gastro-oesophageal junction cancer: an open-label, single-arm, phase 2 trial. The Lancet Oncology. 2020; 21(6): 821-831. doi:10.1016/S1470-2045(20)30169-8.
5. Kang YK, Chen LT, Ryu MH, et al. Nivolumab plus chemotherapy versus placebo plus chemotherapy in patients with HER2-negative, untreated, unresectable advanced or recurrent gastric or gastro-oesophageal junction cancer (ATTRACTION-4): a randomised, multicentre, double-blind, placebo-controlled, phase 3 trial. The Lancet Oncology. 2022; 23(2): 234-247. doi:10.1016/S1470-2045(21)00692-6.
6. NCCN. Esophagus and Esophagastic Juntion Cancers (2.2021). Vol 2.2021. 2.2021.
7. Van Cutsem E, Moiseyenko VM, Tjulandin S, et al. Phase III Study of Docetaxel and Cisplatin Plus Fluorouracil Compared With Cisplatin and Fluorouracil As First-Line Therapy for Advanced Gastric Cancer: A Report of the V325 Study Group. JCO. 2006; 24(31): 4991-4997. doi:10.1200/JCO.2006.06.8429
8. Shah MA, Jhawer M, Ilson DH, et al. Phase II study of modified docetaxel, cisplatin, and fluorouracil with bevacizumab in patients with metastatic gastroesophageal adenocarcinoma. J Clin Oncol. 2011; 29(7): 868-874. doi:10.1200/JCO.2010.32.0770.
9. Đinh Thị Hải Duyên. Đánh giá kết quả điều trị ung thư thực quản giai đoạn tiến triển, di căn bằng phác đồ mDCF. Tạp chí Y học Việt Nam. Published online 2018.
10. Trần Thị Kim Anh, Trịnh Lê Huy. Kết quả điều trị phác đồ m-dcf trong ung thư biểu mô thực quản giai đoạn di căn tại Bệnh viện Đại học Y Hà Nội. VMJ. 2022; 519(1). doi:10.51298/vmj.v519i1.3529.
11. Oken MM, Creech RH, Tormey DC, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol. 1982; 5(6): 649-655.
12. Amin MB, Greene FL, Edge SB, et al. The Eighth Edition AJCC Cancer Staging Manual: Continuing to build a bridge from a population-based to a more “personalized” approach to cancer staging. CA Cancer J Clin. 2017; 67(2): 93-99. doi:10.3322/caac.21388.
13. Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). European Journal of Cancer. 2009; 45(2): 228-247. doi:10.1016/j.ejca.2008.10.026.
14. Hironaka S, Tsubosa Y, Mizusawa J, et al. Phase I/II trial of 2-weekly docetaxel combined with cisplatin plus fluorouracil in metastatic esophageal cancer (JCOG0807). Cancer Sci. 2014; 105(9): 1189-1195. doi:10.1111/cas.12486.
15. Sato Y, Nishida M, Yagi K, et al. Clinical outcome of docetaxel plus cisplatin and fluorouracil (DCF) therapy for metastatic esophageal cancer. Annals of Oncology. 2016; 27: vii75-vii76. doi:10.1093/annonc/mdw521.004.
16. Ghazy HF, El-Hadaad HA, Wahba HA, Abbas R, Abbas OA. Metastatic Esophageal Carcinoma: Prognostic Factors and Survival. J Gastrointest Cancer. 2022; 53(2): 446-450. doi:10.1007/s12029-021-00610-4.
17. Guo X, Qin L, Yang R, Liu Y, Zhou S, Zhao W. Survival outcomes and prognostic factors of early-onset and late-onset metastatic esophageal cancer: a population-based study. Sci Rep. 2025; 15(1): 23588. doi:10.1038/s41598-025-08618-7.
18. Hu B, Zhu Y, Wu X. Comparison of prognostic factors of esophageal cancer between a Chinese cohort and the Surveillance, Epidemiology, and End Results (SEER) database: a retrospective cohort study. J Gastrointest Oncol. 2022; 13(2): 527-538. doi:10.21037/jgo-22-145.